Overview


The term immunoglobulin is used to describe the process of removing antibodies and intravenous immunoglobulin from blood plasma. IVIG is a blood product that is intravenously administered. This therapy is available to individuals who are unable to receive intravenously administered blood products. Antibodies cannot be made in sufficient quantities. Intravenous immunoglobulin therapy is an option for patients with common diseases. Wiskott-Aldrich syndrome, x-linked agammaglobulinemia, and other types of variable immunodeficiency hypogammaglobulinemia. The glycoprotein molecules made by plasma or white blood cells are called immunoglobulins. Immunoglobulins are a critical defense line for the immune system. They recognize and bind to specific proteins, making them a crucial part of your immune system's defense. They can be exposed to specific antigens, such as viruses and bacteria, and help in their destruction. These antibodies are obtained from the plasma of many donors. They can be used to treat many immune-related conditions. Because the body cannot produce antibodies, it can also be used to prophylaxis patients with a weak immune system.

This market is driven by the rising incidence of autoimmune diseases like myasthenia gravis and Guillain Barre syndrome (CIDP), Kawasaki disorder, and thrombotic thrombocytopenicpurpura. The market will also be fueled by government initiatives to raise awareness about autoimmune diseases as well as their treatment options. National Institutes of Health (NIH), launched the "All of Us" precision medical program. This program aims to gather data from more than one million people to create a research resource that will allow scientists to develop new treatments, prevent, or cure diseases based on individual differences in their environment, lifestyle, and genetics. The market will be constrained by the high price of treatment over the forecast period. In remote and poor areas, healthcare infrastructure is more vulnerable. The situation is changing as more organizations work to improve healthcare services in remote areas. As the government is unwilling to pay for certain therapies and treatments, it poses a problem in terms of reimbursement. These may be due to a lack of knowledge about the products or high prices.

High risk of side effects and strict government regulations regarding intravenous immunoglobulin product use They are likely to limit the market's growth. High adoption is the opposite. The potential for intravenous immunoglobulin to treat various diseases will be a lucrative business opportunity. Opportunities in the near future The IVIG market is also hindered by high treatment costs. IVIGproducts can be very costly. Materials required for their production are more expensive and require a greater amount of labor. Donor blood samples are taken. There are also high side-effects of IVIGtreatment. These side-effects limit the growth of intravenous antibody markets. These side effects hinder IVIGproducts acceptance Many patients.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Intravenous Antibodies Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Intravenous Antibodies Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Baxter International inc
  • Beijing Tiantan Biological Products Co Ltd
  • Biotest AG
  • China Biologic Products Inc
  • CSL Limited
  • Guizhou Taibang Biological Products Co Ltd
  • Sanghai RAAS Blood Products Co Ltd
  • Octapharma AG
  • Grifois S.A.
  • Hualan Biological Engineering Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Application

  • Immunodeficiency Diseases
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Idiopathic Thrombocytopenic Pupura
  • Hypogammaglobulinemia
  • Myasthenia Gravis
  • Multifocal Motor Meuropathy
  • Inflammatory Myopathies
  • Specific antibody Deficiency
  • Guillain-barre Syndrome
  • Others

By End-user

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Intravenous Antibodies Market By Type, By Application, By End-user and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Intravenous Antibodies Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Intravenous Antibodies Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Intravenous Antibodies Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Intravenous Antibodies Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD

  • 8.   Intravenous Antibodies Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Immunodeficiency Diseases
        2. Chronic Inflammatory Demyelinating Polyneuropathy
        3. Idiopathic Thrombocytopenic Pupura
        4. Hypogammaglobulinemia
        5. Myasthenia Gravis
        6. Multifocal Motor Meuropathy
        7. Inflammatory Myopathies
        8. Specific antibody Deficiency
        9. Guillain-barre Syndrome
        10. Others

  • 9.   Intravenous Antibodies Market, By End-user Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Others

  • 10.   North America Intravenous Antibodies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Intravenous Antibodies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Intravenous Antibodies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Intravenous Antibodies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Baxter International inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Beijing Tiantan Biological Products Co Ltd
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Biotest AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. China Biologic Products Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. CSL Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Guizhou Taibang Biological Products Co Ltd
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanghai RAAS Blood Products Co Ltd
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Octapharma AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Grifois S.A.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Hualan Biological Engineering Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients